Drug intelligence / Profile preview

anti-miR-345 oligonucleotide

Development stage
Unknown
Modality
Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Subcutaneous, Intratumoral, Intraperitoneal, Intrathecal, Intranasal
01

Overview

Anti-miR-345 oligonucleotide is a synthetic antisense oligonucleotide designed to bind and neutralize the activity of microRNA-345 (miR-345). In oncological research, particularly concerning pancreatic cancer, miR-345 has been identified as a tumor suppressor that targets the anti-apoptotic protein BCL2. While the restoration of miR-345 expression (via mimics) is explored as a therapeutic strategy to induce apoptosis in cancer cells, anti-miR-345 oligonucleotides are primarily utilized as research reagents. They serve to validate the functional specificity of miR-345 by reversing its inhibitory effects on target genes and its induction of programmed cell death in experimental models.

Other names
anti-miR-345anti-miR345anti-miR 345miR-345 inhibitormiR345 inhibitormiR 345 inhibitorantagomir-345antagomir345antagomir 345

Beyond the preview

Go deeper on anti-miR-345 oligonucleotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-miR-345 oligonucleotide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call